Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-05-18
2009-10-27
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S138100, C424S139100, C530S388100
Reexamination Certificate
active
07608264
ABSTRACT:
This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders.
REFERENCES:
patent: 5770421 (1998-06-01), Morris et al.
patent: 6696548 (2004-02-01), Morris et al.
patent: WO-00/20869 (2000-04-01), None
patent: WO-01/96394 (2001-12-01), None
Santa Cruz Biotechnology catalog pages for sc-6345 and sc-6346. No date available.
Ledbetter et al. 1997. Crit Rev Immunol 17:427-435.
Accurate Chemical p80 antibody, catalog No. MEDCLA568-01. No date available.
Kuby 1998. Immunology, 3rd Edition, pp. 92-98.
Fujimoto et al. 1996. Proc Natl Acad Sci USA 93:4181-4186.
Dreyfus 1998 Int J Dev Biol 42:189-198.
Aigner et al., “Identification of a receptor for the growth factor pleiotrophin, its signal transduction and potential role in cancer,” Proceedings of AACR 40:732 (1999).
Albertoni et al., “Genetic instability leads to loss of both p53 alleles in a human glioblastoma,” Oncogene 16(3):321-326 (1998).
Ausbel et al., “Short Protocols in Molecular Biology,” 10.82-10.84 and 11.23-11.25 (1997).
Bashkin et al., “Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules,” Biochemistry 28(4):1737-1743 (1989).
Basilico et al., “The FGF family of growth factors and oncogenes,” In Advances in Cancer Research, Academic Press, Inc., San Diego, CA 59:115-165 (1992).
Bork, “Powers and pitfalls in sequence analysis: the 70% hurdle,” Cold Spring Harbor Laboratory Press 398-400 (2000).
Bowers et al., “Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase-and AKT-dependent pathways,” Cancer Res. 60(16):4277-4283 (2000).
Buczek-Thomas et al., “Elastase-mediated release of heparin sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bFGF binding following elastase-induced injury,” J. Biol. Chem. 274:25167-25172 (1999).
Caughey et al., “Fractionation of polyclonal antibodies to fragments of a neuroreceptor using three increasingly caotropic solvents,” Journal of Chromatography B 728:49-57 (1999).
Chauhan et al., “Pleiotrophin transforms NIH 3T# cells and induces tumors in nude mice,” Proc. Natl. Acad. Sci. USA 90:679-682 (1993).
Choudhurl et al. “An anglogenic role for the neurokines midkine and pleiotrophin in tumorigenesis,” Cancer Res. 59(9):1814-1819 (1997).
Czubayko et al., “A secreted FGF-binding protein can serve as the angiogenic switch in human cancer,” Nat. Med. 3(10)1137-1140 (1997).
Czubayko et al., “Adenovirus-mediated transduction of ribozymes abrogates HER-2
eu and Pleiotrophin expression and inhibits tumor cell proliferation,” Gene Rherapy 4:943-949 (1997).
Czubayko et al., “Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrpphin,” Proc. Natl. Acad. Sci. USA 93:14753-14758 (1998).
Czubayko et al., “Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth,” J. Biol. Chem. 269(33):21358-21363 (1994).
Czubayko et al., “Tumor growth and anglogenesis induced by a secreted binding protain for fibroblast growth factors,” J. Biol. Chem. 269(45):28243-28248 (1994).
Dove, “Proteomics: translating genomics into products?,” Nat. Biotechnol. 17:233-236 (1999).
Fang et al., “Pleiotrophin stimulates fibroblasts and endothellal and epithelial cells and is expressed in human cancer,” J. Biol. Chem. 267(36):25889-25897 (1992).
Fumari et al., “Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain,” Proc. Natl. Acad. Sci. USA 94:12479-12484 (1997).
Genbank Accession No. U66559, created on Feb. 24, 1997, located at <http://www.ncbi.nlm.nih.gov> last visited on Mar. 3, 2005, 3 pages.
Genetwork “Go hunting in sequence database but watch out for the traps,” TIG 12(10):425-427 (1996).
Hanahan et al., “The hallmarks of cancer,” Cell 100:57-70 (2000).
Holland et al., “Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice,” Nat. Genet. 25:55-57 (2000).
Holland, “Glioblastoma multiforme: the terminator,” Proc. Natl. Acad. Sci. USA 97(12):6242-6244 (2000).
Iwahara et al., “Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system,” Oncogene 14:439-449 (1997).
James et al., “Molecular genetics and molecular biology advances in brain tumors,” Curr. Opin. Oncol. 8:188-195 (1996).
Khwaja, “Akt is more than just a bad kinase,” Nature 401:33-34 (1999).
Klagsbrun et al., “A dual receptor system is required for basic fibroblast growth factor activity,” Cell 67(2):229-231 (1991).
Li et al., “Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity,” Science 250:1690-1694 (1990).
Li et al., “PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells,” Proc. Natl. Acad. Sci. USA 95:15406-15411 (1998).
Maeda et al., 684 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase RPTPB, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)271(35):21446-21452 (1996).
Maeda et al., “A receptor-like protein-tyrosine phosphatase PTP/RPTPB binds a heparin-binding growth factor midkine,” 274(18):12474-12479 (1999).
Mashama et al., “PTEN: a tumour suppressor that functions as a phospholipid phosphatase,” rends Cell Biol. 9:125-128 (1999).
Matsumoto et al, “A novel family of heparin-binding growth factors, plelotrophin and midkine, is expressed in the developing rat cerebral cortex,” Developmental Brain Research 79:229-241 (1994).
Meng, “Pleiotrophin signals increased tyrosine phosphorylation of B-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase B/C,” PNAS 97(6):2603-2608 (2000).
Merenmies et al., “Molecular cloning of the 18-kDa growth-associated protein of developing brain,” J. Biol. Chem. 265(28):16721-16724 (1990).
Merz, Jr. et al., “The protein folding problem and lertiary structure prediction,” Birkhauser Boston Ch. 14:433-506 (1994).
Morris et al, ALK, the chromosome 2 gene tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene 14:2175-2188 (1997).
Morris et al., “Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma,” Science 263:1281-1284 (1994).
Morris et al., “Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma: sequence correction,” Erratum Science 267:316-317 (1995).
Motegi et al., “ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth,” J. Cell Science 117:3319-3329 (2004).
Nishikawa et al., “A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity,” Proc. Natl. Acad. Sci. USA 91:7727-7731 (1994).
Nister et al., “Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines,” J. Biol. Chem. 226(25):16755-
Georgetown University
Kolker Daniel E.
Ropes & Gray LLP
LandOfFree
Antibodies that bind to pleiotrophin growth factor receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that bind to pleiotrophin growth factor receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that bind to pleiotrophin growth factor receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4095558